Related Experiment Video
Updated: Aug 9, 2025

Self-Nanoemulsification of Healthy Oils to Enhance the Solubility of Lipophilic Drugs
Published on: July 27, 2022
Low-dose erythromycin in pediatrics: Formulation and stability of 20 mg hard gelatin capsules
Patrick Thevin1, Christophe Curti1,2, Alexandre Benech1
1Service central de la qualité et de l'information pharmaceutiques (SCQIP), Pharmacy Department, AP-HM, Marseille, France.
Insights
Compounded 20 mg erythromycin capsules offer a stable, year-long option for premature neonates needing prokinetic therapy. This formulation addresses the lack of adapted oral erythromycin for high-risk infants.
Area of Science:
- Pharmaceutical Sciences
- Neonatal Pharmacology
Background:
- Erythromycin, a macrolide antibiotic, is used off-label as a prokinetic agent in premature neonates.
- Existing oral formulations lack appropriate dosage and excipients for this vulnerable population.
Purpose of the Study:
- To develop and assess the stability of a compounded oral erythromycin formulation suitable for premature neonates.
- To establish a reliable beyond-use date for the compounded medication.
Main Methods:
- A stability-indicating chromatographic method, as per United States Pharmacopoeia, was employed for analysis.
- 20 mg erythromycin capsules were compounded using microcrystalline cellulose.
- Stability was evaluated for capsules stored at room temperature, protected from light, over one year.
Main Results:
- The compounded 20 mg erythromycin capsules demonstrated stability.
- A beyond-use date of not less than one year was determined for the capsules.
Conclusions:
- Hospital pharmacies can compound 20 mg erythromycin capsules in batches of 300 units.
- These compounded capsules are stable for one year at ambient temperature when protected from light, offering a viable therapeutic option.
Objective:
Erythromycin is a macrolide antibiotic that is also prescribed off-label in premature neonates as a prokinetic agent. There is no oral formulation with dosage and/or excipients adapted for these high-risk patients.
Methods:
Clinical studies of erythromycin as a prokinetic agent were reviewed. Capsules of 20 milligrams of erythromycin were compounded with microcrystalline cellulose. Erythromycin capsules were analyzed using the chromatographic method described in the United States Pharmacopoeia which was found to be stability-indicating. The stability of 20 mg erythromycin capsules stored protected from light at room temperature was studied for one year.
Results:
20 mg erythromycin capsules have a beyond use date not lower than one year.
Conclusion:
20 milligrams erythromycin capsules can be compounded in batches of 300 unities in hospital pharmacy with a beyond-use-date of one year at ambient temperature protected from light.
Related Concept Videos
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Factors Influencing Drug Absorption: Pharmaceutical Parameters
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
Factors Affecting Drug Response: Overview
Dosage Regimen: Fixed Dose
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...

